Paradigm Biopharmaceuticals

Videos

Shareholder Information

Corporate Governance

Announcements

Analyst Reports

Home

Value Proposition

Archivo

investor hub

Explore a curated selection of videos featuring Paradigm’s latest company updates, investor presentations, and media coverage, alongside expert perspectives from external sources. Stay informed on our progress as we advance iPPS to address the global burden of osteoarthritis.

Paradigm founder Mr Paul Rennie provides a presentation at the recent Ausbiz Capital Investor Connect session.

Carlton legend, Mark Murphy, says he is beaten crippling osteoarthritis pain thanks a little-known Australian discovery. Now the drug that helped him could soon be on offer to millions more Australians.

Channel 7 News Report  2023, on IPPS potential as a new treatment for the unmet need in osteoarthritis. Sportspeople Marc Murphy and Rebecca Cole speak of their struggles with osteoarthritis.

Paradigm (ASX:PAR) reports: 65% pain reduction in osteoarthritis patients treated under the US FDA expanded access program. The program treated 10 retired NFL players.

Paradigm Biopharmaceuticals Ltd is pleased to announce the results of its phase 2b randomised double-blind placebo-controlled multi-centre clinical trial.

Paradigm MD, Paul Rennie, discusses the acquisition of Proteobioactives Pty Ltd and how the access to global IP for the combination of PPS and a Cox-2 inhibitor, builds out Paradigms OA portfolio.

Paradigm MD, Paul Rennie, discusses the acquisition of Proteobioactives Pty Ltd and how the access to global IP for the combination of PPS and a Cox-2 inhibitor, builds out paradigm OA portfolio.